Usual Adult Dose for Testicular Cancer

20 mg/m2 by slow IV infusion daily for 5 days per cycle in combination with other approved chemotherapeutic agents

Comments:

• The dosing presented is manufacturer suggested.
• Other doses and combination regimens have been used.

Usual Adult Dose for Ovarian Cancer

75 to 100 mg/m2 by slow IV infusion once every 3 to 4 weeks on Day 1

Comments:

• The dosing presented is manufacturer suggested.
• Other doses and combination regimens have been used.

Usual Adult Dose for Bladder Cancer

50 to 70 mg/m2 by slow IV infusion once every 3 to 4 weeks; for heavily pretreated patients, an initial dose of 50 mg/m2 by slow IV infusion once every 4 weeks is recommended

Comments:

• The dosing presented is manufacturer suggested.
• Other doses and combination regimens have been used.

Usual Pediatric Dose for Testicular Cancer

This drug has been used in pediatric patients; however, the manufacturer does not suggest a dose. Institutional protocol should be consulted.

Usual Pediatric Dose for Ovarian Cancer

This drug has been used in pediatric patients; however, the manufacturer does not suggest a dose. Institutional protocol should be consulted.

Usual Pediatric Dose for Bladder Cancer

This drug has been used in pediatric patients; however, the manufacturer does not suggest a dose. Institutional protocol should be consulted.

Renal Dose Adjustments

Dose reduction or alternative treatment may be necessary in patients with renal impairment.

Liver Dose Adjustments

Data not available

Dose Adjustments

The dose of this drug varies depending on the specific indication for its use, whether other cytotoxic agents are coadministered, and institutional protocol.

Impaired creatinine clearance, myelosuppression, or neuropathy: Consider alternative treatments or dose reductions.

Grade 3 or 4 neuropathy: Consider permanent discontinuation of therapy.

Precautions

US BOXED WARNINGS:
NEPHROTOXICITY:

• This drug can cause severe renal toxicity, including acute renal failure.
• Severe renal toxicities are dose-related and cumulative.
• Ensure adequate hydration and monitor renal function and electrolytes.
• Consider dose reduction or alternative treatments in patients with renal impairment.

• This drug can cause dose-related peripheral neuropathy that becomes more severe with repeated courses.

• This drug can cause severe nausea and vomiting.
• Premedicate with antiemetics.

• This drug can cause severe myelosuppression with fatalities due to infections.
• Monitor blood counts.
• Interruption of therapy may be required.

• Hypersensitivity to the active component or any of the ingredients
• Hypersensitivity to other platinum-containing compounds

Dialysis

Data not available

Other Comments

• This drug should be administered by slow IV infusion. Do not give by rapid IV infusion.
• Pretreatment hydration with 1 to 2 liters of fluid infused for 8 to 12 hours prior to a treatment cycle is recommended.
• Maintain adequate hydration and urinary output for 24 hours after dose administration.
• Administer pretreatment and posttreatment antiemetics as needed.

• Procedures for proper handling and disposal of anticancer drugs should be utilized.

• Needles or IV sets containing aluminum parts that may contact this drug should not be used for preparation or administration. Aluminum reacts with this drug, causing precipitate formation and a loss of potency.

• Peripheral blood counts should be monitored weekly.
• Liver function should be monitored periodically.
• Neurologic examination should be performed regularly.